Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


3 J Bone Miner Res
1 J Clin Endocrinol Metab
1 J Clin Invest
9 Osteoporos Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    J Bone Miner Res

  1. COLAIANNI G, Errede M, Sanesi L, Notarnicola A, et al
    In Reply to the Letter to the Editor: Involvement of Irisin in Age-Related Osteoporosis and Its Inhibitory Effect on the Senescent Marker p21 in Osteoblasts.
    J Bone Miner Res. 2021 Feb 18. doi: 10.1002/jbmr.4268.

  2. SCHOUSBOE JT, Ensrud KE
    Opportunistic Osteoporosis Screening Using Low-Dose Computed Tomography (LDCT): Promising Strategy, but Challenges Remain.
    J Bone Miner Res. 2021 Feb 18. doi: 10.1002/jbmr.4266.

  3. WEIGL M, Kocijan R, Ferguson J, Leinfellner G, et al
    Longitudinal Changes of Circulating miRNAs during Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis.
    J Bone Miner Res. 2021 Feb 17. doi: 10.1002/jbmr.4276.
    PubMed         Abstract available

    J Clin Endocrinol Metab

  4. QU Z, Yang F, Yan Y, Hong J, et al
    Relationship between serum nutritional factors and bone mineral density: a Mendelian randomization study.
    J Clin Endocrinol Metab. 2021 Feb 13. pii: 6134779. doi: 10.1210.
    PubMed         Abstract available

    J Clin Invest

  5. YU M, Pal S, Paterson CW, Li JY, et al
    Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells.
    J Clin Invest. 2021;131.
    PubMed         Abstract available

    Osteoporos Int

  6. SAAG K, Cosman F, De Villiers T, Langdahl B, et al
    Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
    Osteoporos Int. 2021 Feb 19. pii: 10.1007/s00198-020-05785.
    PubMed         Abstract available

  7. BERGMAN J, Nordstrom A, Hommel A, Kivipelto M, et al
    Correction to: Bisphosphonates and mortality: confounding in observational studies.
    Osteoporos Int. 2021 Feb 19. pii: 10.1007/s00198-021-05884.

  8. CHEN YJ, Kung PT, Chou WY, Tsai WC, et al
    Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
    Osteoporos Int. 2020 Mar 27. pii: 10.1007/s00198-020-05399.
    PubMed         Abstract available

  9. CUMMINGS SR, McCulloch C
    Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.
    Osteoporos Int. 2020;31:1019-1021.

  10. CUNDY T
    Treat-to-target-mainstream or marketing?
    Osteoporos Int. 2020;31:1835-1836.

  11. KANIS JA, Cooper C, Dawson-Hughes B, Harvey NC, et al
    FRAX and ethnicity.
    Osteoporos Int. 2020;31:2063-2067.

  12. YANG BR, Cha SH, Lee KE, Kim JW, et al
    Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
    Osteoporos Int. 2021 Feb 16. pii: 10.1007/s00198-020-05801.
    PubMed         Abstract available

  13. HUANG X, Chen B, Thabane L, Adachi JD, et al
    Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis.
    Osteoporos Int. 2021 Feb 17. pii: 10.1007/s00198-021-05865.
    PubMed         Abstract available

  14. DRIESSEN JHM, van Dort MJ, Romme EAPM, Wouters EFM, et al
    Associations between bone attenuation and prevalent vertebral fractures on chest CT scans differ with vertebral fracture locations.
    Osteoporos Int. 2021 Feb 16. pii: 10.1007/s00198-020-05719.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.